Abstract. Background: The acidic tumor microenvironment is associated with progression of cancers. The purpose of this study was to investigate the association between an alkaline diet and the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Eleven advanced or recurrent NSCLC patients with EGFR mutations treated with EGFR-TKI after being instructed to follow an alkaline diet were retrospectively evaluated. Results: The median progression-free survival (PFS) and overall survival (OS) were 19.5 (range=3.1-33.8) and 28.5 (range=15.4-46.6) months. The average dosage of EGFR-TKI was 56±22% of the standard dosage. Urine pH was significantly increased after the alkaline diet (6.00±0.38 vs. 6.95±0.55; p<0.05). Conclusion: An alkaline diet may enhance the effect of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
A causative relationship between diet and cancer risk has not been consistently demonstrated. Prospective cohort studies showed no association between vegetable and fruit intake and reduced cancer risk, although case control studies have supported an association (1, 2) . This inconsistency might be due to confounding factors, poor dietary compliance, and insufficient study duration.
Recent evidence supports the important role of metabolism and inflammation in tumor pathogenesis. A major transcription factor in inflammation, NF-ĸB, was involved in the cytotoxic effect of EGFR-TKI; EGFR mutation-positive lung cancer cells were sensitive to NF-ĸB inhibition (3) . Insulin and insulin-like growth factors might stimulate tumor cell growth, based on the association between diabetes and increased risk of cancers. One metaanalysis showed that the anti-diabetic drug metformin was associated with lower cancer incidence in type 2 diabetes (4).
To date it was understood that cancer cells produce energy via high rates of glycolysis to support their rapid cell cycle (Warburg effect). Many researchers have demonstrated that the pH of the tumor microenvironment is acidic due to lactic acid accumulation through the Warburg effect (5, 6) . Moreover, the carbonic anhydrase isozyme CA9 is ectopically overexpressed in solid tumors, especially in the setting of hypoxia. This enzyme catalyzes the hydration of carbon dioxide to bicarbonate and H + . Amith et al. reported that the activity of Na + /H + exchanger is enhanced on breast cancer cell membranes, which contributes to cytoplasmic alkalization and local extracellular acidosis that regulates tumor proliferation and progression (7) . Na + /H + exchanger is also reported to activate cofilin-1, which is involved in the actin cytoskeleton signaling and plays a key role in cancer cell migration (8) . Therefore, altering pH homeostasis in and around tumor cells might be a critical component of cancer treatment. The purpose of this study was to investigate the association between an alkaline diet and the effect of EGFR-TKI in lung cancer patients with EGFR mutations.
Patients and Methods
Patients. Of the 146 NSCLC patients who visited the Karasuma Wada Clinic between April 2013 and March 2015, there were a total of 45 patients with EGFR mutations who had advanced or recurrent NSCLC. We retrospectively analyzed 11 of these NSCLC patients who were given instructions to change their daily diet to an alkaline diet and then were treated with EGFR-TKI for the first time, regardless of whether they had previously received other treatments. We excluded 25 patients who had previously been treated with EGFR-TKI, 4 patients who did not receive EGFR-TKI treatment, 4 patients who visited our clinic less 5141 This article is freely accessible online. Treatment. The patients in this study were treated with gefitinib, erlotinib, or afatinib. In all cases, the dose of EGFR-TKI was reduced owing to its adverse reactions. This is because several studies have reported that low-dose EGFR-TKI for NSCLC with EGFR mutations produces effective treatment responses similar to treatment with standard dose (9) (10) (11) (12) . Therefore, the patients were treated with the following doses; gefitinib: 125-250 mg/day, erlotinib: 25-100 mg/day, afatinib: 20-40 mg/day. An alkaline diet was defined as that with more vegetables and fruits and less meat and dairy products. All patients in our clinic were given instructions to follow an alkaline diet as part of routine clinical care. At every visit, a doctor or nurse provided patients with instructions on an alkaline diet and assessed whether patients had been following an alkaline diet regularly. 
Results
The median age was 64.4 (range=49-73) years, and there were 6 men and 5 women. Histological examination confirmed that 7 patients had adenocarcinoma and 4 patients had non-small cell carcinoma. Seven patients were recurrent and 4 patients were clinical stage IV. Seven patients had previously undergone chemotherapy before receiving EGFR-TKI treatment. All patients received reduced dosage of EGFR-TKI treatment, and the average dosage of EGFR-TKI was 56±22% of the standard dosage ( Figure 1 ). The median PFS was 19.5 (range=3.1-33.8) months, as shown in Figure 2A , and the median OS was 28.5 (15.4-46.6) months, as shown in Figure 2B . Two of the 11 patients have died as of April 2017. Figure 3 shows the average urine pH of the patients before having an alkaline diet and after having an alkaline diet, until confirmation of progressive disease. A significant difference was observed between urine pH before and after the alkaline diet (6.00±0.38 vs. 6.95±0.55; p<0.05).
Discussion
The most important finding in this report was that the case series of 11 advanced lung cancer patients demonstrated long progression-free survival and overall survival following the combination therapy of low-dose EGFR-TKI with an alkaline diet. The progression-free survival (median=19.5 months) and overall survival (median=28.5 months) of this group was longer than that reported in publications of the similar population treated with EGFR-TKI alone (median progressionfree survival=9.2-13.3 months, median overall survival=18.6-22.8 months) (14) (15) (16) (17) (18) . EGFR-TKI therapy has prolonged progression-free survival of advanced EGFR-mutation positive NSCLC compared to platinum-based chemotherapy, whereas the therapeutic potential of EGFR-TKIs might be limited due to resistance and toxicity (19, 20) . Although this is a preliminary observation in the absence of a comparator group, the consistent outcomes of these 11 cases might suggest the importance of a new regimen that includes an alkaline diet.
In this study, urine pH significantly increased from baseline following initiation of an alkaline diet regimen. Urine pH is an important factor in the development and treatment of kidney stones. For example, the treatment of calcium oxalate stones involves urinary alkalization with sodium or potassium citrate. Besides pharmacologic alkalization, dietary modification also contributes to treatment success. contains alkalotic precursors such as citrate, succinate and malate, which generate bicarbonate. In a study investigating food's influence on urine pH, potential renal acid load was calculated to quantify the acid and base precursors present in food and to predict renal net acid excretion (positive means acidic). Meat had a potential renal acid load of +9.5 mEq, while fruit was -3.1 mEq and vegetables were -2.8 mEq (21) . In the European Prospective Investigation into Cancer and Nutrition-Norfolk population (EPIC) study (n=22,038), alkaline diet with high fruit and vegetable and low meat intake was significantly associated with more alkaline urine (22) . The change in urine pH following an alkaline diet observed in this study was consistent with the EPIC study.
It is difficult to dramatically alter the pH of blood through an alkaline diet, since acid-base balance is maintained by blood and tissue buffers, respiratory CO 2 depletion, and renal regulation of H + excretion and HCO 3 + regeneration. However, both a mathematical model and rat experimental model demonstrated that oral sodium bicarbonate raises extracellular pH of tumor cells (23, 24) . In addition, Robey et al. reported that sodium bicarbonate was significantly associated with reduced number of metastases in rat breast cancer model (24) . This group advocated buffer therapy with sodium bicarbonate to alkalinize urine, neutralize near-tumor acidity, and inhibit tumor metastasis. Our approach with an alkaline diet is similar to buffer therapy, linked by the common concept that intake of an alkaline agent increased urine pH and had an anti-cancer effect. Therefore, these animal data support the association between urinary alkalization and prolonged survival in this study.
We acknowledge that there exist several limitations. First, this study was a retrospective analysis and the sample size was small. Second, lower dosage of EGFR-TKI than the standard was given mainly owing to adverse reactions in this study. Several studies have reported that low-dose EGFR-TKI for EGFR-mutant lung cancer resulted in effective treatment responses (9) (10) (11) (12) . Third, although we showed changes in urine pH in this study, we did not analyze the 
Conclusion
This study demonstrated prolonged progression-free survival and overall survival with the regimen of low-dose EGFR-TKI and an alkaline diet. The significant increase of urine pH suggests that the local acidic pH of tumor might be at least partially neutralized. To the best of our knowledge, this may be the first clinical evidence that an alkaline diet might be associated with better outcomes of advanced lung cancer patients.
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